

Table S1. Clinical Profile

pt	age	sex	group	primary tumor diagnosis (WHO grade)	dd	treatment history
1	63	M	RT	Glioblastoma (IV), IDH-wt, unknown MGMT	301	standard*
2	54	M	RT	Glioblastoma (IV), IDH-wt, MGMT methylated	2472	standard
3	77	M	RT	Glioblastoma (IV), IDH-wt, MGMT methylated	755	standard
4	51	F	RT, H+	Glioblastoma (IV), IDH-wt, unknown MGMT	416	standard + 2 surgeries + study**
5	56	F	RT	Anaplastic Astrocytoma (III), IDH-wt, no MGMT methylation	263	standard
6	22	F	RT	Anaplastic Astrocytoma (III), IDH-wt, MGMT methylated	495	standard
7	70	M	RT, H+	Glioblastoma (IV), IDH-wt, unknown MGMT	425	standard
8	28	F	RT, H+	Glioblastoma (IV), IDH-wt, unknown MGMT	2333	standard
9	51	M	RT	Glioblastoma (IV), IDH-wt, MGMT methylated	593	standard + surgery + study [†]
10	67	M	NRT	Anaplastic Astrocytoma (III), unknown IDH/MGMT	8664	radiation + PCV
11	43	M	NRT	Anaplastic Astrocytoma (III), unknown IDH/MGMT	3629	standard
12	43	M	NRT	Anaplastic Astrocytoma (III), IDH-m, unknown MGMT	2580	resection + radiation + PCV
13	62	M	NRT	Glioblastoma (IV), IDH-wt, unknown MGMT	225	standard
14	68	M	NRT	Glioblastoma (IV), IDH-wt, unknown MGMT	548	standard + surgery
15	79	F	NRT	Glioblastoma (IV), IDH-wt, no MGMT methylation	1535	standard

16	33	F	NRT	Anaplastic Infiltrating Glioma (III), IDH-m, unknown MGMT	1973	standard + Mebendazol
17	41	M	NRT	Anaplastic Astrocytoma (III), IDH-m, no MGMT methylation	2082	standard
18	66	M	NRT	Glioblastoma (IV), IDH-wt, no MGMT methylation	281	standard
19	68	F	NRT	Epitheloid Glioblastoma (IV), IDH-wt, MGMT methylated	121	standard
20	61	F	NRT	Anaplastic Astrocytoma (III), IDH-m, unknown MGMT	4141	standard
21	62	F	NRT	Glioblastoma (IV), IDH-wt, MGMT methylated	458	standard + surgery
22	46	M	NRT	Anaplastic Astrocytoma (III), unknown IDH/MGMT	4383	standard
23	64	F	NRT	Diffuse Oligodendroglioma (III), unknown IDH/MGMT	7165	standard
24	69	M	NRT	Glioblastoma (IV), IDH-wt, unknown MGMT	2364	standard + 2 surgeries
25	47	M	NRT	Glioblastoma (IV), IDH-wt, MGMT methylated	1878	standard + 3 surgeries + study [§] + chemoradiation
26	72	F	NRT	Glioblastoma (IV), IDH-wt, unknown MGMT	1964	Standard
27	43	F	NRT	Anaplastic Astrocytoma (III), unknown IDH/MGMT	4318	standard + Bevacizumab
28	39	M	NRT	Anaplastic Astrocytoma (III), unknown IDH/MGMT	4831	standard + surgery

Pt - patient, dd - days since diagnosis, WHO - World Health Organization, M - male, F - female, RT - residual/recurrent tumor, NRT - no residual/recurrent tumor, H+ - active tumor in histopathology (within 4 weeks of imaging), IDH - isocitrate dehydrogenase, wt - wild type, m - mutated, MGMT - O-6-methylguanine-DNA methyltransferase

PCV - Procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, Lomustine), Vincristine

* standard - 6 weeks of chemoradiation with Temozolomide (Temodar) followed by 6 cycles of adjuvant Temozolomide

** N1604 - Phase 0/I study of AMG 232 at 240 mg 1x daily for 7 consecutive days every 21 days

† J1444 - Glioma Atkins-based Diet study

§ J11120 - Phase II trial with chemo-sensitizing low-dose radiation for 6 months (Radtx 0.5 Gy twice daily on Days 1-5 of the normal 28-day Temodar cycle)